[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"critically-ill-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:critically-ill-patients":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,75,107,133,157,183,210,232,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100566203","immunosuppression-and-intensive-care-unit-acquired-multidrug-resistant-bacteria-100566203",false,"NCT06652126","Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria","Impact of Immunosuppression on Intensive Care Unit-acquired Multidrug-resistant Bacteria: a Prospective Multicenter Study in Europe","TANGERINE","Inclusion Criteria:\n\n1. Patients aged 18 and over.\n2. Admitted to intensive care and whose length of stay is greater than 48 hours (inclusion is at the 48th hour after admission).\n3. Immunocompetent OR immunocompromised patients according to one of the following criteria:\n\n   1. Solid cancer under treatment or in remission for less than 5 years (including cancers diagnosed during hospitalization in intensive care);\n   2. Hematological malignancies under treatment or in remission for less than 5 years (including hematological malignancies diagnosed during hospitalization in intensive care);\n   3. Neutropenia \\< 0.7 G\u002FL for ≥ 7 days;\n   4. Solid organ transplants;\n   5. Patients with systemic or transplant pathologies requiring treatment with corticosteroids (prednisone equivalent \\> 10 mg\u002Fday) or other high-dose immunosuppressants for \\> 28 days;\n   6. Human Immunodeficiency Virus (HIV) infection with CD4+ \\<200 μL;\n   7. Genetic immune deficiency.\n4. Patients undergoing invasive mechanical ventilation and\u002For vasopressive amines.\n5. Persons who have given their non-opposition. For patients unable to give their non-opposition, this will be obtained from the trusted support person. The patient will be informed as soon as possible and asked to agree to participate in any further research.\n6. Patients affiliated to a social security system.\n\nExclusion Criteria:\n\n1. Minor patients (\\< 18 years),\n2. Length of stay in intensive care less than 48 hours,\n3. Moribund patients.\n4. Absence of BMR screening (rectal swab routinely, combined with nasal swab in some centers) within 48 hours of admission.\n5. Refusal to participate in the study.\n6. Vulnerable and\u002For susceptible patients according to one of the following criteria:\n\n   1. Patients under legal protection (guardianship, curatorship, etc.);\n   2. Patients in prison;\n   3. Pregnant or breast-feeding women.\n7. Patients without social security coverage.\n8. Simultaneous participation in another interventional study that could interfere with the evaluation of primary and secondary endpoints (particularly in the case of participation in an interventional study that could modulate the risk of CAR or BMR-ARI).","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Antimicrobial resistance AMR is an emerging global threat to human health, and intensive care units (ICUs) are a 'hot spot' for the emergence and diffusion of multidrug-resistant (MDR) bacteria. ICU-acquired colonization and infection with MDR bacteria (ICU-MDR-col and ICU-MDR-inf, respectively) have been associated with higher ICU length-of-stay, duration of invasive mechanical ventilation and mortality. Immunocompromised patients account for an increasing proportion of ICU patients, and they are particularly prone to ICU-acquired infections, a significant proportion of which are caused by MDR pathogens. Recently, in a prospective multicenter study in France (CIMDREA, 8 ICUs, 750 patients), we found that immunocompromised patients had a lower cumulative incidence of ICU-MRD-col, but not ICU-MDR-inf (after adjustment for confounders). These results suggest that isolation measures and contact precautions could have a protective impact on cross-transmission of MDR bacteria in immunocompromised patients, even though our study fails to provide conclusive arguments for this. If confirmed, these findings could have an impact on antibiotic stewardship in immunocompromised critically-ill patients, a key element to control the spread of AMR in ICUs and beyond. Thus, we are planning to carry out the TANGERINE study, an observational prospective multicenter study in Europe, to confirm the findings of CIMDREA and provide a better understanding of the effect of isolation measures and contact precautions on the epidemiology of AMR in ICUs.",[25],"Critically-ill Patients",[27,28,29,30],"Immunocompromised patients","antimicrobial resistance","intensive care unit","cross-infections","RECRUITING","2026-05-14",{"date":34,"type":35},"2026-05-18","ACTUAL",{"date":37,"type":35},"2025-03-19",{"date":39,"type":21},"2029-12-01",{"name":41,"class":42},"University Hospital, Lille","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100638344","bis-in-critically-ill-patients-in-icu-100638344","NCT07583732","BIS in Critically Ill Patients in ICU","The Comparison of Bispectral Index Parameter Between Critically Ill Patients With and Without Decreased Mental Status and Its Association With Clinical Outcomes","Inclusion Criteria:\n\n1. Age≥18years\n2. RASS score ≤ -3 as case\n3. RASS score 0 to -1 as control\n4. Expected ICU length of stays ≥ 24hours\n\nExclusion Criteria:\n\n1. Contraindication for BIS monitoring (wound or infection at forehead)\n2. No space for attach BIS monitoring at forehead\n3. Patient with sedative drugs (Propofol, Midazolam, Dexmedetomidine)\n4. Patient with acute stroke\n5. Patient was already on EEG monitoring\n6. Denied by patients or patient's surrogates",{"count":52,"type":21},40,"INTERVENTIONAL",[55],"NA","The Bispectral Index (BIS) is a monitor that converts brain electrical activity from EEG into a simple number from 0 to 100. A higher number means the patient is more awake, while a lower number means deeper sedation or reduced brain activity.\n\nIn general, 100 means fully awake, 80 suggests light to moderate sedation, 60 is commonly used as a target for general anesthesia with a low chance of awareness, 40 indicates deep anesthesia, 20 suggests marked brain suppression with burst suppression on EEG, and 0 indicates no detectable cortical electrical activity.\n\nAlthough BIS was originally developed for use in the operating room, it has also been applied in the ICU to help guide sedation, avoid over- or under-sedation, and assess consciousness in patients who cannot be evaluated reliably using standard clinical scores. BIS has also been studied as a possible tool for predicting outcomes in comatose ICU patients, such as those after cardiac arrest, stroke, encephalitis, or traumatic brain injury. However, evidence is still limited for its use in predicting outcomes among ICU patients with any form of decreased consciousness. Therefore, this study was conducted to explore that role.",[58],"Critically Ill Patients",[60,61,62,63,64],"BIS","processed EEG","ICU patient","Sedation","Neuromonitoring","NOT_YET_RECRUITING","2026-05-06",{"date":68,"type":35},"2026-05-13",{"date":70,"type":21},"2026-05-15",{"date":72,"type":21},"2027-03-31",{"name":74,"class":42},"Mahidol University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":53,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":104,"locationsCount":106},"100553467","reliability-of-minimally-trained-operators-velocity-time-integral-measurement-guided-by-artificial-intelligence-vti-100553467","NCT06486467","Reliability of Minimally Trained Operator's Velocity-Time Integral Measurement Guided by Artificial Intelligence VTI","Reliability of Minimally Trained Operator's Velocity-Time Integral Measurement Guided by Artificial Intelligence (MiniTrained-VTI)","MiniTrainedVTI","Inclusion criteria:\n\nAll patients aged 18 and more\n\nHospitalized in ICU, in whom fluid administration is considered necessary by the clinician in charge, based on the presence of hypoperfusion criterion:\n\n* \\>10% decrease in mean arterial pressure with respect to baseline value\n* Skin mottling, oliguria (\\\u003C0,5 ml\u002Fkg\u002Fh)\n* change in the level of consciousness\n* hyperlactatemia\n* decrease in central venous oxygen saturation Affiliation to a French social security system (beneficiary or legal) Participant's or next of kin non-opposition or emergency procedure\n\nExclusion Criteria:\n\nPatients with atrial fibrillation, due to the higher variability in LVOT VTI; Patient on Emergency Medical Assistance; Patient under guardianship, curatorship, deprived of liberty.",{"count":84,"type":21},100,[55],"Stroke volume is a major determinant of tissue perfusion and therefore a key parameter to monitor in patients with hemodynamic instability and hypoperfusion. Left Ventricular Outflow Tract (LVOT) Velocity-Time Integral (VTI) measured using pulsed wave Doppler is widely used as an estimation of stroke volume and should be a competence required for every Intensive Care Unit (ICU) physician. Recently, research in Artificial Intelligence (AI) applied to medical imaging constituted a breakthrough in the acquisition of images. The goal of the present study is to characterize and quantify the reliability and reproducibility of LVOT VTI measurements by comparing the measures obtained by minimally-trained operators and expert physicians, guided by UltraSight AI software.",[88,58,89],"Velocity-time Integral Measurement","Tissue Hypoperfusion",[91,92,93,94,95,96,97],"Velocity-time integral","Echocardiography","Artificial Intelligence","Minimally-trained operator","Reproducibility","Fluid challenge","Fluid responsiveness","2026-04-20",{"date":100,"type":35},"2026-04-21",{"date":102,"type":35},"2024-11-14",{"date":70,"type":21},{"name":105,"class":42},"Assistance Publique - Hôpitaux de Paris",3,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":53,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":43},"100605071","effects-of-compound-ejiao-syrup-on-exercise-tolerance-and-quality-of-life-in-critically-ill-patients-after-icu-discharge-a-double-blind-multicenterrandomized-controlled-clinical-study-100605071","NCT07157748","Effects of Compound Ejiao Syrup on Exercise Tolerance and Quality of Life in Critically Ill Patients After ICU Discharge: A Double-Blind, Multicenter,Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* 1\\. Obtain informed consent; 2. Age between 18 and 75 years (inclusive); 3. Discharged from the ICU within 24 hours; 4. Received mechanical ventilation for at least 48 hours during this ICU stay; 5. Has been in the ICU for at least 8 days but no more than 28 days; 6. Enteral nutrition has been initiated. 7. Able to breathe spontaneously, with an oxygenation index (PaO2\u002FFiO2) ≥ 200, and not requiring continuous high-flow oxygen therapy (e.g., nasal cannula flow ≤ 5 L\u002Fmin); 8. Glasgow Coma Scale (GCS) score ≥ 13 at ICU discharge, and able to cooperate with study-related tests and follow-up; 9. Able to perform simple bedside activities with assistance (e.g., sitting up, standing, or short-distance walking); 10. No severe heart failure, no end-stage chronic respiratory failure, no lower-limb conditions that impair mobility, and no severe central nervous system disease; Able to stand independently and expected to complete the 6MWT at follow-up.\n\nExclusion Criteria:\n\n* 1\\. Patients expected to die or for whom life-sustaining treatment will be withdrawn within 48 hours after ICU discharge; 2. Patients who need to be readmitted to the ICU within 1 week after ICU discharge; 3. Patients with persistent severe hepatic failure at ICU discharge (Child-Pugh class C); 4. Patients with persistent chronic kidney disease at ICU discharge (creatinine clearance \\\u003C 40 mL\u002Fmin); 5. Pregnant or breastfeeding patients; 6. Patients unable to walk independently before ICU admission (those who can walk independently with assistive devices may be included); 7. Traumatic brain injury, primary cerebrovascular diseases, brain tumors, or intracranial infections; 8. Primary cognitive impairment: Alzheimer's disease, vascular dementia, hydrocephalus, etc., and other serious central nervous system diseases; 9. History of psychiatric disorders such as depression, anxiety, or schizophrenia; 10. Occurrence of respiratory or cardiac arrest; 11. Patients with known cognitive impairment, lower-limb injury, systemic neuromuscular disease, or cranial\u002Fspinal conditions that could affect outcome assessment; 12. Patients currently taking other Qi- and blood-tonifying traditional Chinese medicines or patent Chinese medicines.","75 Years",{"count":115,"type":21},178,[55],"This study, titled \"Effect of Compound Ejiao Jiang on Exercise Tolerance and Quality of Life of Critically Ill Patients after Discharge from ICU: A Double-Blind, Multicenter, Randomized Controlled Clinical Study (LIFT Study),\" intends to enroll 156 patients (78 in the experimental group and 78 in the control group). A double-blind design will be adopted, with patients receiving Compound Ejiao Jiang (20 ml each time, three times a day for 90 consecutive days) or a placebo for intervention. The primary outcome measure is the 6-minute walking distance on the 90th day after randomization. Meanwhile, secondary endpoints such as physical function, quality of life, and nutritional and inflammatory indicators will also be monitored. The aim of this study is to explore the rehabilitation value of Compound Ejiao Jiang for patients with post-intensive care syndrome (PICS) through high-level evidence-based medicine methods and to provide scientific evidence for the integrated traditional Chinese and Western medicine approach to improving the long-term prognosis of critically ill patients",[58],[120,121,122,123],"critically ill patients","exercise tolerance","exercise quality","Compound Ejiao Oral Liquid","2025-08-28",{"date":126,"type":35},"2025-09-05",{"date":128,"type":21},"2025-12",{"date":130,"type":21},"2027-09",{"name":132,"class":42},"Third Military Medical University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":142,"studyType":22,"phases":4,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":153,"leadSponsor":155,"locationsCount":43},"100602510","disease-severity-mortality-risk-and-muscle-function-in-intensive-care-unit-patients-100602510","NCT07124442","Disease Severity, Mortality Risk, and Muscle Function in Intensive Care Unit Patients","Relationship of Disease Severity and Mortality Risk With Respiratory Muscle Strength, Muscle Biomechanical Properties, and Muscle Architecture in Intensive Care Unit Patients","Inclusion Criteria:\n\nNot dependent on mechanical ventilation,\n\nPatient or legal representative provides consent to participate,\n\nAged 18 years or older,\n\nMonitored in the ICU for at least 48 hours.\n\nExclusion Criteria:\n\nUnable to obtain ethical consent,\n\nPresence of neuromuscular disease affecting muscle tone,\n\nPatients unable to cooperate during measurement due to impaired consciousness, communication disorder, or other medical reasons,\n\nPresence of infection, open wound, or any lesion impairing skin integrity at the anatomical measurement site.",{"count":141,"type":21},45,"1 Day","Intensive Care Units are specialized, technologically advanced hospital units that provide continuous monitoring and care from multiple healthcare disciplines for patients who are critically ill and face a high risk of death or serious health problems. Prolonged periods of immobility, which are common during treatment in these units, can cause serious complications such as muscle weakness, decline in physical function, and a lower quality of life. There are scoring systems designed to predict the severity of a patient's illness and their likely outcomes, such as the scoring system called the Acute Physiology and Chronic Health Evaluation version two. However, these scoring systems are not yet widely used as a regular part of patient care. Although weakness and wasting of muscles away from the center of the body are known to affect the recovery process of patients who survive intensive care treatment, the connection between how severe the illness is and the strength of the muscles used for breathing, the structure of peripheral muscles, and their biomechanical characteristics is still not fully understood. This study aims to explore these relationships to help improve physiotherapy and rehabilitation treatments for patients in intensive care.",[58],[146,147,148],"Critically ill patients","Respiratory muscle","Skeletal muscle","2025-08-09",{"date":151,"type":35},"2025-08-15",{"date":151,"type":21},{"date":154,"type":21},"2025-10-30",{"name":156,"class":42},"Istinye University",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":106},"100524470","clearance-of-vasoactive-metabolites-with-blood-purification-100524470","NCT06109142","Clearance of Vasoactive Metabolites With Blood Purification","Pilot Study on the Effect of Oxiris Haemofiltration Membrane on Haemodynamic Stabilisation and Clearance of Vasoactive Metabolites","VITAL","Inclusion Criteria:\n\n* Patients admitted to intensive care with vasoplegic shock (hemodynamic support by noradrenaline).\n* Adult or child ≥ 6 years and 30kg\n* Indication for extrarenal purification for acute, chronic renal failure, oliguric hydrosodic overload, refractory metabolic acidosis or severe hydroelectrolyte disorder\n* Clinician's decision to use an oXiris hemofilter with blood purification capability\n* For adult patients: no opposition from the patient (or person of trust or close friend if the patient is unable to be informed)\n* For minor patients: no opposition of the holders of parental authority\n\nExclusion Criteria:\n\n* No need for hemofiltration.\n* Citrate anticoagulation of the hemofiltration circuit\n* Inclusion in a category 1 or 2 interventional study protocol. Patients included in category 3 interventional research will be able to participate in the study after assessment by the physician.\n* Patient under judicial protection and adults under guardianship or curatorship.\n* Patient with no social security affiliation","6 Years",{"count":167,"type":21},30,"Extracorporeal blood purification is a supportive therapy in the management of patients with sepsis or vasoplegic shock. The pathophysiology of sepsis is based on an inappropriate host response to infection. Certain medical devices with higher adsorption capacity make it possible to limit this inappropriate response and could thus improve the hemodynamics of patients in septic or vasoplegic shock. The preliminary experience of the investigators from clinical data of vasopressor withdrawal in pediatric patients treated with oXiris shows a 50% reduction in the vasopressor score, Vaso Inotropic Score (VIS), for 40% of patients within 24 hours following the start of treatment. Similar results were found in adult patients treated for severe COVID-19 or vasoplegic shock by the other centers participating in the study.\n\nCytokine purification is an important physiological effect of purification membranes. However, this may not fully explain the rapid hemodynamic improvement of patients treated with an oXiris membrane.\n\nThe role of angiotensin metabolites (Ang 1-5, 1-7, 1-9) in the systemic vascular tone of patients has been recently discussed. The administration of angiotensin 2 in vasoplegic shock in adults helps correct hypotension. In the group of patients with increased renin, this treatment was associated with a reduction in mortality. Indeed, increased renin associated with dysfunction of Angiotensin Converting Enzyme (ACE) leads to an accumulation of Angiotensin 1 which degrades to Ang 1-7.\n\nThe hypothesis f the investigators is that the concentration of Ang 1 and Ang 1-7 is elevated in cases of vasoplegic shock and that the clearance of these vasodilator peptides by blood purification is associated with clinical improvement.",[58],[171,172,173,174],"Intensive care","Septic shock","Inflammatory mediators","Renin Angiotensin System","2024-09-13",{"date":177,"type":35},"2024-09-19",{"date":179,"type":35},"2024-07-11",{"date":181,"type":21},"2026-06-11",{"name":105,"class":42},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100557860","the-multi-modal-evaluation-of-agitation-in-critically-ill-patients-based-on-remote-video-ultra-sensitive-detection-wave-100557860","NCT06543602","the Multi-modal Evaluation of Agitation in Critically Ill Patients Based on Remote Video-Ultra-sensitive Detection Wave","A Multi-modal Recognition Model and Efficacy Evaluation for Agitation Behavior in Critically Ill Patients Based on Remote -Ultra-sensitive Detection Wave ---A Multi-center, Open-label, Observational Study","Inclusion Criteria:\n\n* Patients at risk of agitation in the ICU\n* Patients with RASS score -2 and above\n* ≦ 65 years old, ≧ 18 years old\n\nExclusion Criteria:\n\n* The affected party refused to participate in this study\n* Missing\u002Fincomplete information\n* Vulnerable groups such as pregnant women, those who lack the capacity for civil conduct and do not have the consent of their legal representatives\n* Maxillofacial trauma, burns, tumors, surgery, etc. affect facial expression\n* Patients with limb impairment and amputation\n* Spinal cord injury, limb movement\u002Fsensory limitations\n* Patients with pre-existing neurological\u002Fpsychiatric diseases\n* Patients with malignant tumors\n* Patients with infectious diseases\n* Patients with terminal disease and dying disease\n* Abnormal behavior due to head injury or craniocerebral disease","65 Years",{"count":192,"type":21},580,"The goal of this observational study is to learn about the effectiveness of the multi-modal evaluation for agitation behavior in critically ill patients based on remote video-Ultra-sensitive detection wave.\n\nThe main question it aims to answer is: evaluate the effectiveness of multi-modal evaluation monitoring system for agitated critically ill patients Participants already taking multi-modal evaluation monitoring system as part of their regular medical care for agitated critically ill patients will compare their effectiveness for agitation for 3 years.",[58],[196,197,198,199],"Critically Ill","agitation","monitoring","remote","2024-08-05",{"date":202,"type":35},"2024-08-09",{"date":204,"type":35},"2024-05-01",{"date":206,"type":21},"2027-04-30",{"name":208,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University",2,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":43},"100365984","impact-of-capillary-leak-and-hypoalbuminemia-on-pkpd-of-anidulafungin-and-caspofungin-in-critically-ill-patients-100365984","NCT04045366","Impact of Capillary Leak and Hypoalbuminemia on PK\u002FPD of Anidulafungin and Caspofungin in Critically Ill Patients","Inclusion Criteria:\n\n* Treatment with anidulafungin or caspofungin\n* Admitted to an ICU ward\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* DNR 2 or 3",{"count":217,"type":21},60,"This prospective study will explore the pharmacokinetic exposure and pharmacodynamics of the echinocandins (caspofungin or anidulafungin) in critically ill patients.",[58],[221,222,146],"Pharmacokinetics","Echinocandins","2024-07-02",{"date":225,"type":35},"2024-07-03",{"date":227,"type":35},"2012-09-21",{"date":229,"type":21},"2025-12-31",{"name":231,"class":42},"Universitaire Ziekenhuizen KU Leuven",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":239,"studyType":22,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":43},"100326406","pharmacokinetics-of-liposomal-amphotericin-b-in-critically-ill-vs-non-critically-ill-hematological-patients-exploration-of-covariates-100326406","NCT03529617","Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates","Inclusion Criteria:\n\n* Treatment with L-AmB\n* Admitted to an ICU or Hematology ward\n\nExclusion Criteria:\n\n* DNR 2 or 3\n* Pregnant or lactating women\n* Previous documentation of intolerance\u002Fsensitivity to L-AmB",{"count":217,"type":21},"1 Month","This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.",[221,242,58],"Liposomal Amphotericin B",{"date":225,"type":35},{"date":245,"type":35},"2016-10-19",{"date":229,"type":21},{"name":231,"class":42},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":257,"conditions":258,"keywords":263,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":43},"100534127","continuous-subcutaneous-glucose-monitoring-in-critical-patients-100534127","NCT06234787","Continuous Subcutaneous Glucose Monitoring in Critical Patients","Continuous Subcutaneous Glucose Monitoring: A Descriptive Study of Its Use in Critical Patients","Inclusion Criteria:\n\n* The study will be conducted in patients admitted to the ICU of HLA Moncloa Hospital over four years. Patients admitted to the ICU, undergoing insulin treatment, and having a CGM sensor.\n* Patients who sign the voluntary consent to participate in the study (Annex 2). If the participant is not in full physical or intellectual capacity to provide their signature on the informed consent, the responsible investigator will request such consent from their direct family member or the person legally designated to make decisions on their behalf regarding health matters. This measure is taken to ensure that the participant\\'s rights are respected, and the integrity of the consent process is maintained, even in situations where their decision-making capacity may be compromised.\n\nExclusion Criteria:\n\n* Patients from whom information on CGM cannot be obtained for technical reasons.",{"count":256,"type":21},245,"This is a single-center, observational, descriptive, longitudinal, and prospective study This study aims to determine the cumulative incidence during admission and the incidence rate of potential hypoglycemic events (defined as subcutaneous glucose \\\u003C80 mg\u002FdL detected by CGM) in patients admitted to the Intensive Care Unit (ICU) of HLA Moncloa Hospital over four years of follow-up. The study also aims to document the occurrences of hypoglycemic events, describe the characteristics of patients receiving CGM sensors, and outline the actions taken as a result of detecting potential hypoglycemic events",[259,260,261,262,58],"Hyperglycemia","Hypoglycemia","Diabetes","Critical Care",[264,265,266,267],"continuous subcutaneous glucose monitoring","critical care","intensive care","hypoglycemia","2024-02-01",{"date":270,"type":35},"2024-02-05",{"date":272,"type":35},"2023-11-30",{"date":274,"type":21},"2027-12-01",{"name":276,"class":42},"Universidad Europea de Madrid"]